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Core tip: This manuscript focuses on the development of
novel technologies to precisely alter the human stem cell
genome and highlights their implications for both basic
and applied stem cell research. Specifically, we discuss
the development of two main technologies: molecular
engineering of viral vectors and design of artificial endonucleases. We also discuss the merits of combining
these complementary approaches and suggest other
possible strategies that could be explored to further improve genetic engineering of human stem cells.

Abstract

Ramamoorthi K, Curtis D, Asuri P. Advances in homology directed genetic engineering of human pluripotent and adult stem
cells. World J Stem Cells 2013; 5(4): 98-105 Available from:
URL: http://www.wjgnet.com/1948-0210/full/v5/i4/98.htm DOI:
http://dx.doi.org/10.4252/wjsc.v5.i4.98

The ability to introduce precise genomic modifications
in human cells has profound implications for both basic and applied research in stem cells, ranging from
identification of genes regulating stem cell self-renewal
and multilineage differentiation to therapeutic gene
correction and creation of in vitro models of human
diseases. However, the overall efficiency of this process
is challenged by several factors including inefficient
gene delivery into stem cells and low rates of homology directed site-specific targeting. Recent studies report the development of novel techniques to improve
gene targeting efficiencies in human stem cells; these
methods include molecular engineering of viral vectors
to efficiently deliver episomal genetic sequences that
can participate in homology directed targeting, as well
as the design of synthetic proteins that can introduce
double-stranded breaks in DNA to initiate such recombination events. This review focuses on the potential
of these new technologies to precisely alter the human
stem cell genome and also highlights the possibilities
offered by the combination of these complementary
strategies.

INTRODUCTION
Gene targeting via homologous recombination (HR)
presents a precise way to manipulate the mammalian genome at specific loci. Such legitimate site-directed gene
targeting requires homology between the donor DNA
and the endogenous chromosome, and results in the substitution of DNA between the homologous donor and
the endogenous chromosomal sequence (Figure 1). Creating or correcting specific mutations in human stem cells
provides great utility in stem cell research; for example,
gene knock-in and knockout studies can be carried out to
identify and study specific genes expressed and involved
in stem cell fate decisions, as well as to create lineage-specific reporter cell lines to screen for signaling pathways in
vitro and to monitor differentiation and proliferation of
stem cells following transplantation in vivo[1-5]. Targeted
gene mutations also facilitate the generation of models
to investigate human developmental diseases and screen
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Figure 1 Random and homologous integration. Introduction of a foreign gene into mammalian cells can either result in its random integration into the endogenous
chromosomal DNA, or site-specific integration at the desired location dictated by the homology between the donor DNA and the endogenous target locus.
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Figure 2 Barriers to gene targeting. The different barriers that gene delivery vectors must
overcome for successful gene targeting include
cell binding and internalization, intracellular trafficking and endosomal escape, translocation
through the nuclear envelope, and efficient sitespecific integration.
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for potential therapies[6]. Therefore, mediating efficient
gene targeting in human stem cells impacts the future application of these cells in tissue engineering, regenerative
medicine, and high-throughput drug discovery and toxicology. Current strategies to manipulate the mammalian
cell genome are mostly viral-based; several viral gene delivery systems, including adenovirus, retrovirus, and lentivirus provide high transduction efficiencies, integration
into the host cell genome, and high levels of gene expression[7-9]. Lentiviral vectors in particular are highly efficient
and result in stable, long-term transgene expression without gene silencing and have been extensively employed in
studies of human stem cells[9]. However, viral approaches
are often complicated by random vector integration into
the host genome that results in genomic instability leading to increased risk of oncogenesis, a major concern for
downstream clinical applications[10,11]. In contrast, nonviral methods, such as encapsulation of DNA by lipid
or cationic polymer vesicles and naked DNA delivery by
either physical (electroporation) or chemical methods,
deliver DNA episomally and therefore can in principle
avoid insertional mutagenesis due to random integration; however, their application for gene targeting is often
restricted by inefficient delivery and by the inability to
provide sustained gene expression[12,13]. Thus, despite the
enormous potential of genetically modified stem cells
in basic and translational research, low rates of targeted
gene modifications in human stem cells have limited the
realization of these applications.

WJSC|www.wjgnet.com

This review focuses on recent advances in gene targeting techniques, with particular emphasis on technologies that significantly enhance the rates of homology
directed genetic engineering of human pluripotent and
adult stem cells. These advances open up a range of
experimental and therapeutic possibilities, including instruction of stem cell differentiation into therapeutically
relevant cells and development of stem cell-based disease
models for drug development.

BARRIERS TO GENE TARGETING
Low efficiencies of gene targeting can result from a combination of extracellular and intracellular barriers and increasing our understanding of the contributions of these
barriers to gene targeting, as well as strategies to successfully overcome them will benefit the design of efficient
vectors for enhanced gene transfer and targeting. The
series of barriers that challenge the progress of the gene
targeting constructs to the cell nucleus include inefficient
transport across the cell membrane and the nuclear envelope, as well as diffusional and metabolic barriers of
the cytoplasm that reduce the amount of intact donor
DNA constructs that reach the nuclear envelope (Figure
2)[13-16]. Inside the nucleus, exogenous DNA can integrate
at predetermined sites via homologous recombination
into the genome, although in general the rates of random
integration are far greater than those of homologous integration; this low spontaneous frequency of site-specific
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integration necessitates identification of the small fraction of cells undergoing homologous integration by a
combination of positive and negative selection, which
require considerable time and expertise[17,18].
Recent years have witnessed the emergence of two
main strategies to overcome these barriers: (1) molecular
engineering of viral vectors to improve their safety and
efficiency and (2) artificial endonucleases that introduce
site-specific DNA double-stranded breaks to stimulate
targeted integration. Here we will review the use of these
novel technologies to carry out homology directed gene
knock-outs, knock-ins, and corrections in human stem
cells and their potential for advancing basic and applied
stem cell research.

four- to five-fold higher than the endogenous mutated
ABCD1 gene. Furthermore, after 20-24 mo, the VLCFA
levels in patients decreased by up to 39%. Finally, IDLVs
encoding for cytokines have been used to induce human
monocytes to differentiate into dendritic cells and the
resulting induced dendritic cells were functional and capable of stimulating multivalent immune responses in vitro and in vivo[23]. In addition to developing non-integrative
vectors, researchers are also pursuing approaches to engineer safer viral vectors by overriding the intrinsic preferences of viral genomic integration for transcriptional
start sites (TSS); for example, Lim et al[24] discovered that
the addition of DNA binding domains at key sites within
retroviral vectors shifted their integration patterns toward
regions where TSS are relatively rare. Another approach
is the incorporation of Cre recombinase into lentiviral
vectors for directed gene targeting[25]. Although this approach is limited by Cre’s specificity for loxP sites that are
not native to the mammalian genome, researchers have
reported the presence of pseudo loxP sites in the human
genome that can be targeted by either wild-type Cre or
Cre variants[26].
Recently, adeno-associated virus (AAV) based gene
targeting vectors have attracted significant attention as an
alternative to the more commonly used lentivirus- and
adenovirus-based vectors, mainly because of their ability
to deliver transgenes in episomal form and mediate longterm gene expression in dividing and non-dividing cells
of numerous human tissues[27]. Additionally, it has been
demonstrated that AAV vectors can also be used to introduce site-specific genetic modifications in human cells
with high efficiencies (up to 1%) that are 103-104-fold
higher than plasmid constructs delivered using electroporation[28]. There is evidence supporting that AAV
genome’s inverted terminal repeats facilitate its stable
integration into the host cell genome using the RAD51/
RAD54 pathway of HR in eukaryotes[29]. The ability of
AAV to introduce targeted genetic modifications in human cells has been exploited in a variety of applications
including the creation of isogenic (knock-in) cells that
could be used to study cancer genes in a high-throughput
manner. Di Nicolantonio et al[30] recently used this approach to evaluate the effect of drugs on isogenic breast
epithelial cells expressing wild-type and mutant alleles
of BRAF, KRAS, PIK3CA, and EGFR genes previously
implicated in oncogenic pathways. Erlotinib and gefitinib
(EGFR tyrosine kinase inhibitors) were shown to prevent
cell proliferation and induce apoptosis selectively in cells
carrying the EGFR delE746-A750 deletion, while the
cells with KRAS or BRAF mutations were more resistant
to these drugs.
AAV-based vectors have also been evaluated for their
ability to perform HR mediated gene targeting in human stem cells, and these studies revealed that the genetargeting frequency for AAV-based vectors was about 1
× 10-5; the low frequencies observed in this study could
be attributed to low efficiency of naturally occurring
AAV variants in mediating gene delivery to human stem

MOLECULAR ENGINEERING OF VIRAL
VECTORS
Lentivirus-based gene delivery vectors have been widely
examined for in vivo and in vitro applications owing to
their inherent advantages - specifically, they can efficiently
transduce both dividing and non-dividing cells, can be
pseudotyped to optimize tropism to a specific cell or
tissue of interest, can transduce both dividing and nondividing cells, and do not induce significant immune responses[19,20]. However, their broad applicability has been
limited by the risk of mutagenesis associated with random vector integration into the target genome. Recently,
it has been demonstrated that the random insertion event
can be prevented by simply introducing mutations in the
integrase protein of the virus that facilitates viral genome
integration[21]. Such integrase-deficient lentiviral vectors
(IDLV) represent new avenues for targeted genetic engineering of human stem cells due to their ability to deliver
episomal donor DNA for homologous recombination,
while retaining their unique ability to efficiently infect
both dividing and non-dividing cells. For example, IDLV
have been shown to efficiently transduce both dividing
(human embryonic kidney 293) and non-dividing cells
(primary neurons and astrocytes) in vitro. And the transgene expression, monitored using GFP fluorescence,
was transient in dividing cells and stable in non-dividing
cells, consistent with transcription from episomal genetic
sequences. Moreover, residual integration activity studies confirmed significantly reduced occurrence (102-103
fold lower) of integration events compared to wild-type
lentiviral vectors. IDLVs have also been used to provide
clinical benefits for patients with X-Linked adrenoleukodystrophy (ALD)[22]. ALD is caused by a mutation in the
ABCD1 gene encoding for the ALD protein, which leads
to accumulation of abnormally high levels of very long
chain fatty acids (VLCFAs) causing the adrenal cortex
and the myelin membranes that surround nerves to cease
functioning. A lentiviral vector encoding the wild-type
ABCD1 was introduced into CD34+ cells obtained from
ALD patients and the transformed cells were then reinfused into patients. Quantitative analysis using RT-PCR
showed that the expression of ABCD1 transgene was
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cells[31,32]. Directed evolution approaches, therefore, have
been applied to rapidly engineer AAV mutants with the
capacity for high efficiency gene delivery to human adult
and pluripotent stem cells. Unlike the more deliberate
rational design approaches where the virus is modified
based on an understanding of the mechanistic consequences of a particular set of changes, directed evolution
is a rapid, high-throughput selection approach to create
and isolate novel virus mutants with specific properties
of interest through appropriate selection pressures from
millions of genetic variants. Central to the approach is
the highly evolvable AAV capsid that determines the viral
infectivity and tropism. This approach employs iterative
rounds of genetic diversification, either via error-prone
PCR or DNA shuffling and artificial selection pressures
to incrementally alter the desired phenotypes. For example, it has been demonstrated that directed evolution
of AAV capsids can be used to select variants with the
ability to evade antibody neutralization and deliver genes
more efficiently that wild-type AAV[33] (Figure 3). Other
successful examples include the isolation of AAV variants with altered receptor binding and cell tropism in vitro
and in vivo, and enhanced gene delivery[34,35]. Using this
approach, researchers have recently created a novel AAV
variant - AAV r3.45 that mediates efficient gene delivery
to both murine (infection efficiency > 40%) and human
(infection efficiency > 30%) neural stem cells (NSCs)
when compared to naturally occurring AAV variants
(infection efficiency < 1%)[36]. More importantly, this
increase in gene delivery efficiency was accompanied by
up to 10-fold enhancement in the ability to repair singlebase pair mutations in rat NSCs, relative to naturally
occurring AAV. In a related study, researchers have also
demonstrated the ability of directed evolution approaches to isolate a new AAV variant, AAV 1.9 that exhibited
enhanced gene delivery to both human embryonic stem
cells (ESCs) and induced pluripotent stem cells (iPSCs)
(infection efficiencies: 40%-50%) that was accompanied
by a corresponding increase in AAV 1.9’s capacity for
gene targeting, with efficiencies as high as 0.12%, in human ESCs and iPSCs[37].
Another strategy that has been used to improve the
ability of AAV vectors to deliver genes to human cells
is to facilitate AAV’s intracellular trafficking (from the

WJSC|www.wjgnet.com

Figure 3 Schematic of steps in the directed evolution of
adeno-associated virus. The wild-type adeno-associated
virus (AAV) cap genes are mutated to create large genetic
libraries (1) and the mutant cap genes are packaged to generate libraries of AAV particles (2), with each AAV composed
of a variant capsid surrounding a viral genome encoding
that capsid. The resulting AAV libraries can be subjected to
appropriate selective pressures (3) to isolate vectors with
modified capsids that facilitate the AAV variants to efficiently
surmount these pressures (4). Examples include isolation of
AAV variants with the ability to evade neutralizing antibodies, altered receptor binding and cell tropism, and enhanced
gene delivery. Successful AAV variants are amplified and
recovered (6), or can be subjected to additional rounds of
mutagenesis and selection (5). Adapted from Maheshri et
al[33] and Bartel et al[35].

cytoplasm to the nucleus) following cellular uptake. Previous studies have shown that inhibition of the EGFRPTK mediated phosphorylation of AAV capsid proteins
at tyrosine residues results in decreased ubiquitination of
AAV capsids and their proteasome-mediated degradation, thereby enabling nuclear transport of AAV vectors
and improved gene delivery to the cell nucleus[38]. Based
on these results, Zhong et al[39] hypothesized that substitution of surface-exposed tyrosine residues on AAV capsids may lead to the design of AAV vectors that facilitate
efficient delivery of genes to the nucleus of target cells
at lower doses. Consistent with this hypothesis, they observed that site-directed mutagenesis of surface-exposed
tyrosine residues significantly improve the transduction
efficiency of AAV vectors (about 10-fold increase) in human epithelial cells in vitro. It has also been demonstrated
that tyrosine mutant AAV vectors display enhanced gene
delivery efficiencies in vivo when compared to wild-type
AAV vectors[40]. Although further investigation is warranted, such enhanced AAV vectors engineered through
rational design to avoid cytoplasmic degradation could
also potentially enhance the efficiencies of AAV-mediated
gene targeting in human stem cells.

INTRODUCTION OF SITE-SPECIFIC DNA
DOUBLE-STRANDED BREAKS
It has been previously demonstrated that the rate of
homologous recombination with donor DNA can be
enhanced by the introduction of double-stranded breaks
(DSBs) in the mammalian genome using nucleases such
as I-SceI[41]. Building upon this important prior work, scientists have recently developed highly specific nucleases
such as zinc finger nucleases that can be in principle engineered to target and introduce DNA DSBs at any site in
the genome and thus facilitate targeted modifications of
endogenous genes. Zinc finger nucleases (ZFNs) are synthetic proteins composed of a DNA-binding domain that
can be engineered to target desired DNA sequences fused
to a non-specific endonuclease domain usually derived
from the FokI enzyme[42]. The zinc finger binding domain
contains several amino acids stabilized by a zinc ion; such
zinc finger domains used in tandem can guide the nonspecific DNA cleaving domain to create a double-strand
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ends are compatible; however, when the two ends are
not compatible then NHEJ is prone to cause mutations
(insertion or deletion), thereby knocking out the gene
(Figure 4C). The ability of ZFNs to facilitate targeted
gene knockouts has been recently exploited to disrupt the
CCR5 gene in human CD4+ T-cells[43]. CCR5 is a co-receptor used by the human immunodeficiency virus (HIV)
to infect cells of the immune system; the disrupted gene
produces malformed CCR5 proteins and confers resistance to HIV infection. The safety and efficacy of T-cells
modified by ZFNs targeting the CCR5 gene are currently
being evaluated in a clinical trial (ClinicalTrials.gov identifier NCT00842634). Continuing to build upon this work,
researchers have also used ZFNs to disrupt the CCR5
gene in human hematopoietic stem/progenitor cells[44],
and this approach may lead to providing individuals with
a self-renewable and potentially lifelong source of HIVresistant immune cells.
In contrast, DNA repair using the HR pathway relies
on a homologous DNA sequence that promotes accurate repair of DSBs (Figure 4B). In addition to gene
knockout, this approach also allows precise correction
of mutated or dysfunctional human genes to restore
normal function[45,46] and targeted gene addition into a
specified location in the human cellular genome[47]. Correction of endogenous genes in human cells was first
demonstrated in a study using ZFNs that recognize an
X-linked severe combined immune deficiency mutation
in the IL2Rγ gene, with targeting frequencies as high
as 5.3% in human CD4+ T-cells[45]. Recently, it has also
been demonstrated that ZFNs can enable targeted gene
correction in human embryonic and induced pluripotent
stem cells; in this study, the authors demonstrate gene
targeting efficiencies of up to 0.24% when the cells were
cotransfected with donor DNA and ZFNs specific to
the target site, a > 2400-fold increase in the gene correction efficiencies when compared to without ZFNs (<
10-6). This ability of ZFNs to facilitate site-specific gene
corrections has immense potential to facilitate the generation of genetically corrected, patient-derived cells for
autologous transplantation therapies. Recently, Joung and
coworkers demonstrated in situ correction of the disease
causing mutation in iPSCs derived from sickle cell anemia patients[48]. Finally, homology directed gene addition
has also been demonstrated in human pluripotent stem
cells; ZFNs can be used to target both expressed (OCT4)
and non-expressed (PITX3) genes in human pluripotent
stem cells and knock-in reporter genes (eGFP) to create
reporter cell lines[47]. ZFNs can also be used to knock-in
mutations in the mammalian genome to generate in vitro
models of human disease. For example, Soldner et al[49]
reported the use of ZFNs to develop genetically defined
human in vitro models of Parkinson’s disease (PD) by introducing PD-causing α-synuclein mutations into hESCs.
Despite the huge therapeutic potential for ZFNs there
are complications with toxicity and specificity. Extensive
testing of several variants of ZFNs is required to find the
right ZFN pair to minimize off-target binding, therefore
making the process both time-consuming and expensive.
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Figure 4 Gene editing using Zinc finger nucleases. A: Schematic showing
a zinc finger nuclease (ZFN) dimer bound to its target locus to introduce a sitespecific double-stranded break (DSB) in the chromosome, each ZFN monomer
consists of three to six zinc finger domains fused to the DNA-cleavage domain
of the FokI endonuclease. B: The DNA DSB can be repaired via either the homologous recombination (HR), or C: the non-homologous end-joining pathway.
HR requires a homologous DNA template to accurately repair DSBs in the chromosome, and ensures high fidelity DNA repair. In contrast, non-homologous
end joining does not rely on sequence homology between the DNA ends for
ligation and can be error-prone.

break at a specific target site within a genome. The cleavage domain must dimerize in order to become active and
cleave DNA, thus two ZFN subunits are assembled as
heterodimers at the target cleavage site (Figure 4A). Such
double-strand breaks are typically repaired by two cellular
repair pathways: non-homologous end joining (NHEJ)
and homologous recombination (Figure 4B and C).
NHEJ is the major DNA DSB repair pathway in eukaryotic cells and it repairs DNA breaks by direct ligation
without the need for a homologous template. Typically,
this repair pathway does not create mutations if the two
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Recent discoveries of proteins in bacterial pathogens in
plants have revealed new DNA binding domains: TAL
effectors, which have tandem repeats of amino acids that
bind to a single base pair of DNA. These TAL effectors in conjunction with the Fok1 nuclease (TALENs)
have been shown to function similar to ZFNs[50,51]. The
TALEN technology provides scientists with an increase
in modularity allowing for the creation of many variants
at little time and cost. Although in its infancy, this new
technology has shown great promise; TALEN-mediated
double-strand breaks have initiated HR at similar frequencies and precision as ZFNs in human stem cells. For
example, Hockemeyer et al[52] demonstrated the use of
TALENs to target three endogenous loci (PPP1R12C,
OCT4, and PITX3) in hESCs and iPSCs at efficiencies
comparable to those reported for ZFNs for the same
loci. TALENs have also been recently used to generate
human stem cell-based disease models. Cowan and coworkers reported the generation and use of TALEN
pairs to efficiently generate mutant alleles of 15 genes in
human somatic and pluripotent stem cells and observed
minimal off-target events. Further, they demonstrated
the utility of TALEN-mediated gene editing to develop
detailed genotype-phenotype relationships for four genes
known to be directly linked to various human disease
conditions[53]. Despite these advances, further research
is required to fully evaluate the potential of TALENs
before they replace ZFNs for facilitating targeted gene
modifications in human stem cells.

that baculoviral and IDLV vectors can be used to codeliver both ZFNs and DNA donor templates to induce
efficient gene targeting in human stem cells[54-56]. In these
cases, researchers observed high rates of homology directed gene targeting accompanied by low frequencies of
random chromosomal integration.
Other strategies may explore the possibility of combining rational vector design with directed evolution for example, can gene delivery efficiencies of engineered
AAV vectors evolved to infect human stem cells be further improved by site-directed mutagenesis of surfaceexposed tyrosine residues?
In summary, the considerable progress in enhancing
the capacity for homology directed gene targeting bear
profound implications on basic and applied human stem
cell research. Combining complementary approaches and
as-of-yet unexplored possibilities offered by such strategies will yield the next set of developments in this exciting and challenging field.

REFERENCES
1

2
3

CONCLUSION AND FUTURE
PERSPECTIVES
This review highlights the development of two complementary approaches to efficiently modify the human
stem cell genome. The first approach involves molecular
engineering of viruses, either via rational design or directed evolution, to yield novel vectors that can mediate
safe and efficient gene targeting in human stem cells. The
second approach is the design of custom endonucleases
to target unique predetermined sites in the human genome and facilitate efficient homologous recombination
with donor DNA. Each approach individually has yielded
remarkable enhancements in gene targeting efficiencies
and it is possible that a combination of these complementary approaches can further enhance gene targeting.
For example, it has recently been demonstrated that an
evolved AAV variant can function effectively in conjunction with ZFNs to mediate highly efficient gene targeting
(> 1%) in human pluripotent stem cells. In this study, it
was observed that novel AAV vectors can be created to
mediate efficient gene targeting in human pluripotent
stem cells and in the presence of targeted DSBs generated by the evolved AAV mediated co-delivery of ZFNs,
these efficiencies can be further enhanced[37]. The observed enhancements in gene targeting efficiencies of engineered viral vectors in the presence of local DSBs are
not limited to AAV; researchers have also demonstrated

WJSC|www.wjgnet.com

4

5

6

7
8
9

10

11

103

Kärner E, Unger C, Cerny R, Ahrlund-Richter L, Ganss B,
Dilber MS, Wendel M. Differentiation of human embryonic
stem cells into osteogenic or hematopoietic lineages: a dosedependent effect of osterix over-expression. J Cell Physiol
2009; 218: 323-333 [PMID: 18932205 DOI: 10.1002/jcp.21605]
Bu L, Gao X, Jiang X, Chien KR, Wang Z. Targeted conditional gene knockout in human embryonic stem cells. Cell Res
2010; 20: 379-382 [PMID: 20142843 DOI: 10.1038/cr.2010.23]
Davis RP, Grandela C, Sourris K, Hatzistavrou T, Dottori M, Elefanty AG, Stanley EG, Costa M. Generation of
human embryonic stem cell reporter knock-in lines by
homologous recombination. Curr Protoc Stem Cell Biol
2009; Chapter 5: Unit 5B.1 1.1-134 [PMID: 19885825 DOI:
10.1002/9780470151808.sc05b01s11]
Fischer Y, Ganic E, Ameri J, Xian X, Johannesson M, Semb
H. NANOG reporter cell lines generated by gene targeting
in human embryonic stem cells. PLoS One 2010; 5 [PMID:
20824089 DOI: 10.1371/journal.pone.0012533]
Kammili RK, Taylor DG, Xia J, Osuala K, Thompson K,
Menick DR, Ebert SN. Generation of novel reporter stem
cells and their application for molecular imaging of cardiacdifferentiated stem cells in vivo. Stem Cells Dev 2010; 19:
1437-1448 [PMID: 20109065 DOI: 10.1089/scd.2009.0308]
Urbach A, Schuldiner M, Benvenisty N. Modeling for
Lesch-Nyhan disease by gene targeting in human embryonic stem cells. Stem Cells 2004; 22: 635-641 [PMID: 15277709
DOI: 10.1634/stemcells.22-4-635]
Tashiro K. Optimization of adenovirus vectors for transduction in embryonic stem cells and induced pluripotent stem
cells. Yakugaku Zasshi 2011; 131: 1333-1338 [PMID: 21881308]
Blesch A. Lentiviral and MLV based retroviral vectors for
ex vivo and in vivo gene transfer. Methods 2004; 33: 164-172
[PMID: 15121171 DOI: 10.1016/j.ymeth.2003.11.005]
Gropp M, Reubinoff B. Lentiviral vector-mediated gene
delivery into human embryonic stem cells. Methods Enzymol 2006; 420: 64-81 [PMID: 17161694 DOI: 10.1016/
s0076-6879(06)20005-3]
Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F,
Wulffraat N, McIntyre E, Radford I, Villeval JL, Fraser CC,
Cavazzana-Calvo M, Fischer A. A serious adverse event
after successful gene therapy for X-linked severe combined
immunodeficiency. N Engl J Med 2003; 348: 255-256 [PMID:
12529469 DOI: 10.1056/nejm200301163480314]
Li Z, Düllmann J, Schiedlmeier B, Schmidt M, von Kalle C,

October 26, 2013|Volume 5|Issue 4|

Ramamoorthi K et al . Genetic engineering of human stem cells

12
13
14
15
16

17

18

19
20
21
22

23

24

25
26
27
28
29

Meyer J, Forster M, Stocking C, Wahlers A, Frank O, Ostertag W, Kühlcke K, Eckert HG, Fehse B, Baum C. Murine
leukemia induced by retroviral gene marking. Science 2002;
296: 497 [PMID: 11964471 DOI: 10.1126/science.1068893]
Gao X, Kim KS, Liu D. Nonviral gene delivery: what we
know and what is next. AAPS J 2007; 9: E92-E104 [PMID:
17408239 DOI: 10.1208/aapsj0901009]
Al-Dosari MS, Gao X. Nonviral gene delivery: principle,
limitations, and recent progress. AAPS J 2009; 11: 671-681
[PMID: 19834816 DOI: 10.1208/s12248-009-9143-y]
Kay MA. State-of-the-art gene-based therapies: the road
ahead. Nat Rev Genet 2011; 12: 316-328 [PMID: 21468099
DOI: 10.1038/nrg2971]
Wagstaff KM, Jans DA. Nucleocytoplasmic transport of
DNA: enhancing non-viral gene transfer. Biochem J 2007;
406: 185-202 [PMID: 17680778 DOI: 10.1042/bj20070505]
Lechardeur D, Lukacs GL. Nucleocytoplasmic transport of
plasmid DNA: a perilous journey from the cytoplasm to the
nucleus. Hum Gene Ther 2006; 17: 882-889 [PMID: 16972756
DOI: 10.1089/hum.2006.17.882]
Mansour SL, Thomas KR, Capecchi MR. Disruption of the
proto-oncogene int-2 in mouse embryo-derived stem cells:
a general strategy for targeting mutations to non-selectable
genes. Nature 1988; 336: 348-352 [PMID: 3194019 DOI:
10.1038/336348a0]
Kobayashi K, Ohye T, Pastan I, Nagatsu T. A novel strategy
for the negative selection in mouse embryonic stem cells
operated with immunotoxin-mediated cell targeting. Nucleic
Acids Res 1996; 24: 3653-3655 [PMID: 8836200]
Cockrell AS, Kafri T. Gene delivery by lentivirus vectors.
Mol Biotechnol 2007; 36: 184-204 [PMID: 17873406]
Vigna E, Naldini L. Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene
therapy. J Gene Med 2000; 2: 308-316 [PMID: 11045424]
Staunstrup NH, Mikkelsen JG. Integrase-defective lentiviral
vectors--a stage for nonviral integration machineries. Curr
Gene Ther 2011; 11: 350-362 [PMID: 21745178]
Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Bougnères
P, Schmidt M, Kalle CV, Fischer A, Cavazzana-Calvo M,
Aubourg P. Lentiviral hematopoietic cell gene therapy for
X-linked adrenoleukodystrophy. Methods Enzymol 2012; 507:
187-198 [PMID: 22365775 DOI: 10.1016/b978-0-12-386509-0.
00010-7]
Daenthanasanmak A, Salguero G, Borchers S, Figueiredo C,
Jacobs R, Sundarasetty BS, Schneider A, Schambach A, EizVesper B, Blasczyk R, Weissinger EM, Ganser A, Stripecke
R. Integrase-defective lentiviral vectors encoding cytokines
induce differentiation of human dendritic cells and stimulate multivalent immune responses in vitro and in vivo.
Vaccine 2012; 30: 5118-5131 [PMID: 22691433 DOI: 10.1016/
j.vaccine.2012.05.063]
Lim KI, Klimczak R, Yu JH, Schaffer DV. Specific insertions
of zinc finger domains into Gag-Pol yield engineered retroviral vectors with selective integration properties. Proc Natl
Acad Sci USA 2010; 107: 12475-12480 [PMID: 20616052 DOI:
10.1073/pnas.1001402107]
Michel G, Yu Y, Chang T, Yee JK. Site-specific gene insertion
mediated by a Cre-loxP-carrying lentiviral vector. Mol Ther
2010; 18: 1814-1821 [PMID: 20628360 DOI: 10.1038/mt.2010.150]
Thyagarajan B, Guimarães MJ, Groth AC, Calos MP. Mammalian genomes contain active recombinase recognition
sites. Gene 2000; 244: 47-54 [PMID: 10689186]
Flotte TR, Carter BJ. Adeno-associated virus vectors for
gene therapy. Gene Ther 1995; 2: 357-362 [PMID: 7584109]
Russell DW, Hirata RK. Human gene targeting by viral
vectors. Nat Genet 1998; 18: 325-330 [PMID: 9537413 DOI:
10.1038/ng0498-325]
Vasileva A, Linden RM, Jessberger R. Homologous recombination is required for AAV-mediated gene targeting.
Nucleic Acids Res 2006; 34: 3345-3360 [PMID: 16822856 DOI:

WJSC|www.wjgnet.com

30
31

32
33

34

35

36

37

38

39

40

41

42
43

44

104

10.1093/nar/gkl455]
Di Nicolantonio F, Arena S, Gallicchio M, Bardelli A. Isogenic mutant human cells: a new tool for personalized cancer medicine. Cell Cycle 2010; 9: 20-21 [PMID: 20016269]
Mitsui K, Suzuki K, Aizawa E, Kawase E, Suemori H, Nakatsuji N, Mitani K. Gene targeting in human pluripotent
stem cells with adeno-associated virus vectors. Biochem Biophys Res Commun 2009; 388: 711-717 [PMID: 19695233 DOI:
10.1016/j.bbrc.2009.08.075]
Khan IF, Hirata RK, Russell DW. AAV-mediated gene targeting methods for human cells. Nat Protoc 2011; 6: 482-501
[PMID: 21455185 DOI: 10.1038/nprot.2011.301]
Maheshri N, Koerber JT, Kaspar BK, Schaffer DV. Directed
evolution of adeno-associated virus yields enhanced gene
delivery vectors. Nat Biotechnol 2006; 24: 198-204 [PMID:
16429148 DOI: 10.1038/nbt1182]
Kwon I, Schaffer DV. Designer gene delivery vectors: molecular engineering and evolution of adeno-associated viral
vectors for enhanced gene transfer. Pharm Res 2008; 25:
489-499 [PMID: 17763830 DOI: 10.1007/s11095-007-9431-0]
Bartel MA, Weinstein JR, Schaffer DV. Directed evolution
of novel adeno-associated viruses for therapeutic gene delivery. Gene Ther 2012; 19: 694-700 [PMID: 22402323 DOI:
10.1038/gt.2012.20]
Jang JH, Koerber JT, Kim JS, Asuri P, Vazin T, Bartel M,
Keung A, Kwon I, Park KI, Schaffer DV. An evolved adenoassociated viral variant enhances gene delivery and gene
targeting in neural stem cells. Mol Ther 2011; 19: 667-675
[PMID: 21224831 DOI: 10.1038/mt.2010.287]
Asuri P, Bartel MA, Vazin T, Jang JH, Wong TB, Schaffer
DV. Directed evolution of adeno-associated virus for enhanced gene delivery and gene targeting in human pluripotent stem cells. Mol Ther 2012; 20: 329-338 [PMID: 22108859
DOI: 10.1038/mt.2011.255]
Zhong L, Zhao W, Wu J, Li B, Zolotukhin S, Govindasamy
L, Agbandje-McKenna M, Srivastava A. A dual role of
EGFR protein tyrosine kinase signaling in ubiquitination
of AAV2 capsids and viral second-strand DNA synthesis.
Mol Ther 2007; 15: 1323-1330 [PMID: 17440440 DOI: 10.1038/
mt.sj.6300170]
Zhong L, Li B, Mah CS, Govindasamy L, Agbandje-McKenna M, Cooper M, Herzog RW, Zolotukhin I, Warrington
KH, Weigel-Van Aken KA, Hobbs JA, Zolotukhin S, Muzyczka N, Srivastava A. Next generation of adeno-associated
virus 2 vectors: point mutations in tyrosines lead to highefficiency transduction at lower doses. Proc Natl Acad Sci
USA 2008; 105: 7827-7832 [PMID: 18511559 DOI: 10.1073/
pnas.0802866105]
Petrs-Silva H, Dinculescu A, Li Q, Min SH, Chiodo V, Pang
JJ, Zhong L, Zolotukhin S, Srivastava A, Lewin AS, Hauswirth WW. High-efficiency transduction of the mouse retina
by tyrosine-mutant AAV serotype vectors. Mol Ther 2009;
17: 463-471 [PMID: 19066593 DOI: 10.1038/mt.2008.269]
Choulika A, Perrin A, Dujon B, Nicolas JF. Induction of
homologous recombination in mammalian chromosomes
by using the I-SceI system of Saccharomyces cerevisiae. Mol
Cell Biol 1995; 15: 1968-1973 [PMID: 7891691]
Kim YG, Cha J, Chandrasegaran S. Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. Proc
Natl Acad Sci USA 1996; 93: 1156-1160 [PMID: 8577732]
Perez EE, Wang J, Miller JC, Jouvenot Y, Kim KA, Liu
O, Wang N, Lee G, Bartsevich VV, Lee YL, Guschin DY,
Rupniewski I, Waite AJ, Carpenito C, Carroll RG, Orange JS,
Urnov FD, Rebar EJ, Ando D, Gregory PD, Riley JL, Holmes
MC, June CH. Establishment of HIV-1 resistance in CD4+
T cells by genome editing using zinc-finger nucleases. Nat
Biotechnol 2008; 26: 808-816 [PMID: 18587387 DOI: 10.1038/
nbt1410]
Holt N, Wang J, Kim K, Friedman G, Wang X, Taupin V,
Crooks GM, Kohn DB, Gregory PD, Holmes MC, Cannon

October 26, 2013|Volume 5|Issue 4|

Ramamoorthi K et al . Genetic engineering of human stem cells

45

46

47

48

49

50

PM. Human hematopoietic stem/progenitor cells modified
by zinc-finger nucleases targeted to CCR5 control HIV-1 in
vivo. Nat Biotechnol 2010; 28: 839-847 [PMID: 20601939 DOI:
10.1038/nbt.1663]
Urnov FD, Miller JC, Lee YL, Beausejour CM, Rock JM, Augustus S, Jamieson AC, Porteus MH, Gregory PD, Holmes
MC. Highly efficient endogenous human gene correction
using designed zinc-finger nucleases. Nature 2005; 435:
646-651 [PMID: 15806097 DOI: 10.1038/nature03556]
Zou J, Maeder ML, Mali P, Pruett-Miller SM, ThibodeauBeganny S, Chou BK, Chen G, Ye Z, Park IH, Daley GQ,
Porteus MH, Joung JK, Cheng L. Gene targeting of a disease-related gene in human induced pluripotent stem and
embryonic stem cells. Cell Stem Cell 2009; 5: 97-110 [PMID:
19540188 DOI: 10.1016/j.stem.2009.05.023]
Hockemeyer D, Soldner F, Beard C, Gao Q, Mitalipova M,
DeKelver RC, Katibah GE, Amora R, Boydston EA, Zeitler B,
Meng X, Miller JC, Zhang L, Rebar EJ, Gregory PD, Urnov
FD, Jaenisch R. Efficient targeting of expressed and silent
genes in human ESCs and iPSCs using zinc-finger nucleases. Nat Biotechnol 2009; 27: 851-857 [PMID: 19680244 DOI:
10.1038/nbt.1562]
Sebastiano V, Maeder ML, Angstman JF, Haddad B, Khayter C, Yeo DT, Goodwin MJ, Hawkins JS, Ramirez CL,
Batista LF, Artandi SE, Wernig M, Joung JK. In situ genetic
correction of the sickle cell anemia mutation in human induced pluripotent stem cells using engineered zinc finger
nucleases. Stem Cells 2011; 29: 1717-1726 [PMID: 21898685
DOI: 10.1002/stem.718]
Soldner F, Laganière J, Cheng AW, Hockemeyer D, Gao Q,
Alagappan R, Khurana V, Golbe LI, Myers RH, Lindquist S,
Zhang L, Guschin D, Fong LK, Vu BJ, Meng X, Urnov FD,
Rebar EJ, Gregory PD, Zhang HS, Jaenisch R. Generation
of isogenic pluripotent stem cells differing exclusively at
two early onset Parkinson point mutations. Cell 2011; 146:
318-331 [PMID: 21757228 DOI: 10.1016/j.cell.2011.06.019]
Mussolino C, Morbitzer R, Lütge F, Dannemann N, Lahaye
T, Cathomen T. A novel TALE nuclease scaffold enables
high genome editing activity in combination with low toxic-

51

52

53

54

55

56

ity. Nucleic Acids Res 2011; 39: 9283-9293 [PMID: 21813459
DOI: 10.1093/nar/gkr597]
Li T, Huang S, Jiang WZ, Wright D, Spalding MH, Weeks
DP, Yang B. TAL nucleases (TALNs): hybrid proteins composed of TAL effectors and FokI DNA-cleavage domain.
Nucleic Acids Res 2011; 39: 359-372 [PMID: 20699274 DOI:
10.1093/nar/gkq704]
Hockemeyer D, Wang H, Kiani S, Lai CS, Gao Q, Cassady
JP, Cost GJ, Zhang L, Santiago Y, Miller JC, Zeitler B, Cherone JM, Meng X, Hinkley SJ, Rebar EJ, Gregory PD, Urnov
FD, Jaenisch R. Genetic engineering of human pluripotent
cells using TALE nucleases. Nat Biotechnol 2011; 29: 731-734
[PMID: 21738127 DOI: 10.1038/nbt.1927]
Ding Q, Lee YK, Schaefer EA, Peters DT, Veres A, Kim K,
Kuperwasser N, Motola DL, Meissner TB, Hendriks WT,
Trevisan M, Gupta RM, Moisan A, Banks E, Friesen M,
Schinzel RT, Xia F, Tang A, Xia Y, Figueroa E, Wann A, Ahfeldt T, Daheron L, Zhang F, Rubin LL, Peng LF, Chung RT,
Musunuru K, Cowan CA. A TALEN genome-editing system
for generating human stem cell-based disease models. Cell
Stem Cell 2013; 12: 238-251 [PMID: 23246482 DOI: 10.1016/
j.stem.2012.11.011]
Händel EM, Gellhaus K, Khan K, Bednarski C, Cornu
TI, Müller-Lerch F, Kotin RM, Heilbronn R, Cathomen T.
Versatile and efficient genome editing in human cells by
combining zinc-finger nucleases with adeno-associated viral
vectors. Hum Gene Ther 2012; 23: 321-329 [PMID: 21980922
DOI: 10.1089/hum.2011.140]
Lei Y, Lee CL, Joo KI, Zarzar J, Liu Y, Dai B, Fox V, Wang
P. Gene editing of human embryonic stem cells via an engineered baculoviral vector carrying zinc-finger nucleases.
Mol Ther 2011; 19: 942-950 [PMID: 21326219 DOI: 10.1038/
mt.2011.12]
Lombardo A, Genovese P, Beausejour CM, Colleoni S, Lee
YL, Kim KA, Ando D, Urnov FD, Galli C, Gregory PD, Holmes MC, Naldini L. Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral
vector delivery. Nat Biotechnol 2007; 25: 1298-1306 [PMID:
17965707 DOI: 10.1038/nbt1353]
P- Reviewers Holan V, Thompson EW, Thomas X
S- Editor Qi Y L- Editor A E- Editor Wang CH

WJSC|www.wjgnet.com

105

October 26, 2013|Volume 5|Issue 4|

Published by Baishideng Publishing Group Co., Limited
Flat C, 23/F., Lucky Plaza,
315-321 Lockhart Road, Wan Chai, Hong Kong, China
Fax: +852-65557188
Telephone: +852-31779906
E-mail: bpgoffice@wjgnet.com
http://www.wjgnet.com

Baishideng Publishing Group Co., Limited

© 2013 Baishideng. All rights reserved.

